Related references
Note: Only part of the references are listed.Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer
Liang Chang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma
Meiying Luo et al.
CELLULAR SIGNALLING (2018)
MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1
Yanfen Yao et al.
ONCOTARGETS AND THERAPY (2018)
Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer
Chun-Ni Fan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b
Pengmu Xie et al.
CANCER BIOMARKERS (2018)
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
Paola Martinelli et al.
GUT (2017)
miR-216b inhibits glioma cell migration and invasion through suppression of FoxM1
Tingting Zhang et al.
ONCOLOGY REPORTS (2017)
BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management
Michelle V. Lee et al.
RADIOGRAPHICS (2017)
Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy
Laura K. Ferris et al.
JAMA DERMATOLOGY (2017)
microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo
Mengyao Sun et al.
CELL BIOLOGY INTERNATIONAL (2017)
MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1
Y. Liu et al.
CANCER GENE THERAPY (2017)
miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP
Samir Jana et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Predictive Value of Plasma MicroRNA-216a/b in the Diagnosis of Esophageal Squamous Cell Carcinoma
Shuling Dong et al.
DISEASE MARKERS (2016)
Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines
Douglas F. Dluzen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
GATA6 is overexpressed in breast cancer and promotes breast cancer cell epithelial-mesenchymal transition by upregulating slug expression
Yongchun Song et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2015)
The emerging role of IncRNAs in cancer
Maite Huarte
NATURE MEDICINE (2015)
Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients
V. Vlaeminck-Guillem et al.
PROGRES EN UROLOGIE (2015)
miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells
Yasunori Fujita et al.
PROSTATE (2015)
MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway
F-y Liu et al.
CELL DEATH & DISEASE (2015)
IncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals
Zhen Xing et al.
CELL (2014)
Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin
Pedram Gerami et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway
Dong Li et al.
MOLECULAR MEDICINE REPORTS (2014)
FANTOM: Functional and taxonomic analysis of metagenomes
Kemal Sanli et al.
BMC BIOINFORMATICS (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Landscape of transcription in human cells
Sarah Djebali et al.
NATURE (2012)
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Rajnish A. Gupta et al.
NATURE (2010)
MiR-34a Attenuates Paclitaxel-Resistance of Hormone-Refractory Prostate Cancer PC3 Cells Through Direct and Indirect Mechanisms
Keitaro Kojima et al.
PROSTATE (2010)
Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma
Baojin Fu et al.
CANCER BIOLOGY & THERAPY (2008)
Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer
Kevin A. Kwei et al.
PLOS GENETICS (2008)
Paclitaxel and docetaxel in prostate cancer
C Obasaju et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2001)
Share Paper
